Sofinnova Partners

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Signadori Bio is a biopharmaceutical company dedicated to developing innovative cellular immunotherapy treatments for cancer. It operates in the cell and gene therapy space, aiming to advance novel approaches in oncology to help doctors combat cancer more effectively.

Forth Therapeutics is a biotechnology company specializing in the development of precision treatments for fibrotic diseases. The company employs advanced computational models and machine learning algorithms to integrate single cell and spatial genomics data, enabling it to identify antifibrotic targets with high precision. This approach allows Forth Therapeutics to create detailed maps of fibrotic diseases, accelerating the discovery and development of precision drugs.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

nChroma Bio is a biotechnology company specializing in targeted genetic medicine. It operates an integrated product engine for safe, accurate, and targeted in vivo administration, aiming to overcome limitations of current genetic medicine techniques. The company focuses on liver-targeted therapies, initially for chronic hepatitis B and D, leveraging epigenetics to enable precise and specific gene regulation. This approach allows for therapies with programmable tissue specificity, potentially offering durable and targeted cures for the liver and other organs.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

DISCO Pharmaceuticals is a biotechnology company focused on advancing cancer treatment through its innovative surfaceome mapping platform. The firm specializes in large-scale surfaceome unlocking of cancer cells, utilizing transformative cell discovery technology to identify proteins and protein communities present on the surface of cancer cells. This scalable approach allows for the extraction of comprehensive target information that traditional proteomics, genome, or transcriptome sequencing methods cannot provide. By leveraging this technology, DISCO Pharmaceuticals aims to enable the development of cancer-selective therapies, potentially enhancing treatment efficacy while minimizing side effects for patients.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Freya Biosciences is a clinical-stage company specializing in women's health. It develops microbial immunotherapies, focusing on unmet needs across various indications.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Mediar Therapeutics is a pre-clinical stage biotechnology company focused on developing therapeutics to treat fibrosis in chronically damaged organs. It designs antibodies that neutralize mediators driving fibrotic activity with the aim of halting and reversing fibrosis to improve patient outcomes. Founded in 2019 and based in Cambridge, Massachusetts, the company targets key fibrotic mediator proteins to address late-stage disease with precision and efficacy.

Nuage Therapeutics is a pharmaceutical company specializing in the development of selective drugs targeting proteins with disordered regions. It employs chemical biology and biomolecular condensation to create innovative treatments for challenging indications, focusing on intrinsically disordered targets to address unmet medical needs.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Mablink Bioscience is a biotechnology company focused on developing a new class of cancer therapies known as Antibody Drug Conjugates (ADCs). The company specializes in designing homogeneous, plasma-stable ADCs that maintain their original pharmacological properties while achieving a high drug-to-antibody ratio (DAR). This innovative approach aims to provide healthcare professionals with enhanced treatment options for cancer patients, ultimately improving therapeutic outcomes.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers unique products and collaborative research and development services that aid in the discovery of new cell strains and molecules. Its cell analysis systems facilitate the screening and isolation of rare and valuable biological variants, catering to various applications in research, therapeutic development, bioproduction, and diagnostics. By streamlining these processes, Sphere Fluidics enables clients to reduce costs and time, thereby accelerating advancements in biological and biopharmaceutical discovery.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

Alia Therapeutics develops gene-editing medicines to treat rare genetic diseases. It focuses on next-generation CRISPR technologies that expand targetable genomic sites and improve modification precision, enabling therapies with greater specificity and safety that address genetic disorders at their roots.

Mnemo Therapeutics is a biotechnology company developing immune-based therapies, including cell therapies. Its EnfiniT platform uses epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes across various cancers.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

PinCell is a biotechnology company dedicated to developing innovative treatments for dermatological diseases, particularly those that are orphan conditions. The company focuses its research on identifying novel therapeutic molecules that target specific pathways involved in the pathomechanisms of inflammatory and neoplastic skin diseases. By addressing unmet medical needs in this area, PinCell aims to provide effective therapies for patients suffering from various skin disorders. Through its commitment to research and development, the company seeks to advance the understanding and treatment of these challenging conditions.

Genespire is a biotechnology company dedicated to developing innovative gene therapies for patients suffering from genetic diseases, with a particular emphasis on primary immunodeficiencies and inherited metabolic disorders. The company specializes in creating therapies that utilize integration-defective lentiviral vectors combined with gene editing techniques. This approach allows for highly effective and adaptable targeted insertion of therapeutic genes into blood cells, providing patients with a range of tailored therapeutic options suited to their specific conditions. By focusing on transformative solutions, Genespire aims to significantly improve the lives of individuals affected by severe genetic disorders.

Epsilen Bio Srl is a biotechnology company based in Milan, Italy, specializing in the development of transformative therapies for patients with underserved medical conditions. Founded in December 2019, the company focuses on genomic epigenetic silencing, a technique aimed at stably silencing genes that contribute to various pathological processes. By leveraging this innovative approach, Epsilen Bio aims to provide new therapeutic options that address significant gaps in current medical treatments, ultimately enhancing patient care and outcomes.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Redx Pharma is a UK-based biotechnology company established in 2010, specializing in drug discovery and development. It focuses on improving existing drug classes to create best-in-class new drugs for cancer, fibrosis, and related diseases. The company's portfolio includes RXC004 (porcupine inhibitor) in Phase I clinical trials for various cancers, ROCK inhibitors for inflammatory disease-related fibrosis, and Pan-RAF inhibitor for colorectal cancer. Redx Pharma has collaborations with global pharmaceutical companies and the NHS.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Inotrem is a biotechnology company specializing in immunotherapy for acute and chronic inflammatory syndromes. It has developed a proprietary technology platform targeting the TREM-1 pathway to control unbalanced inflammatory responses, leading to the creation of nangibotide (LR12), a first-in-class TREM-1 inhibitor with potential applications in septic shock and myocardial infarction.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.

Comet Therapeutics, established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing novel small-molecule treatments for various diseases, with a focus on orphan neurological disorders. The company's core technology is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism, thereby addressing significant unmet medical needs in these areas.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

LimFlow is a medical technology company focused on developing innovative solutions for treating end-stage chronic limb ischemia (CLI) patients. Its flagship product, the LimFlow System, utilizes a novel percutaneous procedure to restore blood flow to the ischemic foot by diverting blood around diseased arteries into the tibial vein. This approach is designed to provide an elevated flow of oxygenated blood, thereby alleviating ischemic pain, promoting wound healing, reducing the risk of amputations, and enhancing patient mobility. Currently approved for sale in CE-mark regulated markets, the LimFlow System is also undergoing investigational use in the United States, where it offers new hope to patients who have exhausted other revascularization options. LimFlow emphasizes a multi-disciplinary team approach to maximize the benefits of its technology.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

SafeHeal is a medical device company specializing in digestive surgery. It develops and manufactures a vacuum-based, flexible bypass sheath designed to protect a gastrointestinal anastomosis after colorectal cancer surgery, remaining in place during healing to reduce ostomy needs and support postoperative recovery. The company originated as the first venture created and incubated by MD Start, a medtech accelerator, with backing from MD Start and Sofinnova Partners.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, specializes in developing innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and operating as a subsidiary of Zambon S.p.A., the company focuses on creating novel formulations of existing drugs combined with advanced inhalation technologies. Their drug-device combinations are designed to deliver high concentrations of therapeutics directly to the lungs, enhancing efficacy while minimizing systemic exposure. This approach targets rare respiratory diseases with significant unmet medical needs, positioning Breath Therapeutics at the forefront of inhalation therapy advancements.

HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating first-in-class cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. Utilizing a proprietary siRNA-based screening technology, iOmx systematically analyzes human tumor cells to identify innovative therapeutic targets and understand their mechanisms of action. The company's approach is rooted in the principles of cancer immune-checkpoint therapy, which aims to overcome tumors' inherent resistance to immune attacks. This resistance is often mediated by cell surface molecules that inhibit T cell activation. By neutralizing these negative interactions, iOmx Therapeutics seeks to reactivate the host immune response, ultimately enhancing the effectiveness of cancer treatments.

Delinia, Inc. is a biotechnology company based in San Francisco, California, founded to develop innovative therapeutics targeting autoimmune and inflammatory diseases. The company's primary focus is on a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining immune system homeostasis and self-tolerance. Delinia's lead program aims to enhance the function of these powerful immune cells, providing potential new treatment avenues for patients suffering from autoimmune conditions. Since its incorporation in 2014, Delinia has been guided by a team of scientific founders and experienced executives dedicated to advancing its therapeutic programs into clinical development.

Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.